Int. J. Mol. Sci. 2016, 17(5), 677; doi:10.3390/ijms17050677
Erythropoietin Pathway: A Potential Target for the Treatment of Depression
School of Basic Medical Sciences, Beijing University of Chinese Medicine, School of Basic Medical Sciences, 11 Beisanhuandong Road, Chao Yang District, Beijing 100029, China
†
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Kenji Hashimoto
Received: 5 March 2016 / Revised: 5 April 2016 / Accepted: 27 April 2016 / Published: 6 May 2016
(This article belongs to the Section Biochemistry, Molecular and Cellular Biology)
Abstract
During the past decade, accumulating evidence from both clinical and experimental studies has indicated that erythropoietin may have antidepressant effects. In addition to the kidney and liver, many organs have been identified as secretory tissues for erythropoietin, including the brain. Its receptor is expressed in cerebral and spinal cord neurons, the hypothalamus, hippocampus, neocortex, dorsal root ganglia, nerve axons, and Schwann cells. These findings may highlight new functions for erythropoietin, which was originally considered to play a crucial role in the progress of erythroid differentiation. Erythropoietin and its receptor signaling through JAK2 activate multiple downstream signaling pathways including STAT5, PI3K/Akt, NF-κB, and MAPK. These factors may play an important role in inflammation and neuroprogression in the nervous system. This is particularly true for the hippocampus, which is possibly related to learning, memory, neurocognitive deficits and mood alterations. Thus, the influence of erythropoietin on the downstream pathways known to be involved in the treatment of depression makes the erythropoietin-related pathway an attractive target for the development of new therapeutic approaches. Focusing on erythropoietin may help us understand the pathogenic mechanisms of depression and the molecular basis of its treatment. View Full-TextKeywords:
depression; major depressive disorder; erythropoietin; EPO; hippocampal; anti-depressant targets; drug treatment; signaling pathway
▼
Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Ma, C.; Cheng, F.; Wang, X.; Zhai, C.; Yue, W.; Lian, Y.; Wang, Q. Erythropoietin Pathway: A Potential Target for the Treatment of Depression. Int. J. Mol. Sci. 2016, 17, 677.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Int. J. Mol. Sci.
EISSN 1422-0067
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert